Selective targeting of the TREML1/MD2 interaction by small peptide or protein and its use for vaccine adjuvants
AssigneeAscendo Biotechnology, Inc.
InventorsYen-Ta Lu, Chia-Ming Chang, Ping-Yen Huang, I-Fang Tsai
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition for boosting an immune response contains TREM-like transcript-1 (TREML1) extracellular domain (ECD) or stalk polypeptide. The TREML1 ECD or stalk polypeptide is derived from human or mouse TREML1. The pharmaceutical composition further contains an antigen as a vaccine, wherein the TREML1 ECD or stalk polypeptide functions as an adjuvant or immune booster.
Claims15
A method of boosting an immune response against cancer cells in a subject in need thereof, wherein the method comprises:
- administering a pharmaceutical composition comprising a cancer vaccine and a soluble TREM-like transcript-1 (TREML1) to the subject, the soluble TREML1 comprising a TREML1 extracellular domain (ECD) or TREML1 stalk polypeptide;
- and
- inhibiting growth of the cancer cells, wherein the inhibition of the growth of the cancer cells is higher as compared to the pharmaceutical composition comprising the cancer vaccine without the soluble TREML1, thereby boosting an immune response against the cancer cells in the subject.
A method of enhancing a TLR-induced activation of cells, wherein the method comprises;
- administering a pharmaceutical composition comprising a TLR agonist and a soluble TREML1 to the cells, the soluble TREML1 comprising TREML1 ECD or TREML1 stalk polypeptide;
- and
- inducing a higher level of TLR-induced activated cells as compared to the pharmaceutical composition comprising the TLR agonist without the soluble TREML1, thereby enhancing a TLR-induced activation of cells.
Dependencies are inferred from the claim text.